Sanara MedTech price target raised to $51 from $50 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Sanara MedTech (SMTI) to $51 from $50 and keeps a Buy rating on the shares following the Q4 report. The firm says the company has made “significant progress” in developing the technology platform and infrastructure for Tissue Health Plus, a value-based wound care program.